IRLA
IRLA clinical trials: IRulya Therapeutics Inc.
Every trial on ClinicalTrials.gov where IRulya Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 7
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IRLA on the catalyst calendar · IRLA registry changes
- Primary completion Dec 2028Sponsor estimatePhase 2NCT07886554LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)IRulya Therapeutics Inc. · Sarcoidosis Associated Pulmonary HypertensionNot yet recruitingIRLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 2NCT05798923LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)IRulya Therapeutics Inc. · Pulmonary Hypertension Due to Lung Diseases and HypoxiaRecruitingIRLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2023ActualPhase 2NCT05163886Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral SclerosisIRulya Therapeutics Inc. · Amyotrophic Lateral SclerosisCompletedIRLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 9, 2020ActualPhase 1NCT02594384A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaIRulya Therapeutics Inc. · Lymphoma, Non-Hodgkin; Leukemia, Chronic LymphocyticCompletedIRLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2020ActualPhase 1NCT03426605A Study of LAM-003 in Patients With Acute Myeloid LeukemiaIRulya Therapeutics Inc. · OncologyCompletedIRLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2021ActualPhase 2NCT04446377A Study of LAM-002A for the Prevention of Progression of COVID-19IRulya Therapeutics Inc. · COVID-19 DiseaseCompletedIRLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05483322An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)IRulya Therapeutics Inc. · Frontotemporal DementiaNo longer availableIRLALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06018766LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.Steven Hays, MD · Bronchiolitis Obliterans SyndromeRecruitingIRLACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner